Summit Therapeutics (SMMT) Consolidated Net Income (2016 - 2024)
Historic Consolidated Net Income for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.
- Summit Therapeutics' Consolidated Net Income fell 8122.89% to -$65.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$65.6 million, marking a year-over-year increase of 3237.67%. This contributed to the annual value of -$234.7 million for FY2024, which is 6183.55% up from last year.
- Summit Therapeutics' Consolidated Net Income amounted to -$65.6 million in Q4 2024, which was down 8122.89% from -$60.8 million recorded in Q3 2024.
- In the past 5 years, Summit Therapeutics' Consolidated Net Income ranged from a high of -$9.0 million in Q1 2020 and a low of -$65.6 million during Q4 2024
- Its 4-year average for Consolidated Net Income is -$32.8 million, with a median of -$20.5 million in 2023.
- As far as peak fluctuations go, Summit Therapeutics' Consolidated Net Income crashed by 22950.72% in 2020, and later plummeted by 2096.81% in 2023.
- Quarter analysis of 4 years shows Summit Therapeutics' Consolidated Net Income stood at -$9.0 million in 2020, then plummeted by 125.55% to -$20.3 million in 2022, then crashed by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
- Its Consolidated Net Income stands at -$65.6 million for Q4 2024, versus -$60.8 million for Q3 2024 and -$36.2 million for Q4 2023.